Literature DB >> 7212507

Hepatotoxicity due to treatment with verapamil.

S J Brodsky, S S Cutler, D A Weiner, M D Klein.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7212507     DOI: 10.7326/0003-4819-94-4-490

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  9 in total

Review 1.  A comparative review of the adverse effects of calcium antagonists.

Authors:  H T Dougall; J McLay
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

2.  Verapamil-induced hepatotoxicity.

Authors:  K L Kumar; C A Colley
Journal:  West J Med       Date:  1994-05

Review 3.  Adverse reactions to calcium antagonists.

Authors:  J G Lewis
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

4.  Liver damage from verapamil.

Authors:  P Guarascio; C D'Amato; P Sette; A Conte; G Visco
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-04

5.  Tiapamil, a new calcium channel blocking agent for the treatment of effort induced chronic stable angina pectoris.

Authors:  N S Khurmi; C W Robinson; M J O'Hara; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 7.  Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 8.  Types, causes, and therapies of hepatitis occurring in liver transplant recipients.

Authors:  S Fagiuoli; G Shah; H I Wright; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

9.  Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Authors:  M Lehnert; K Mross; J Schueller; B Thuerlimann; N Kroeger; H Kupper
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.